Apollomics Inc., a biopharmaceutical company, has established an 'At the Market' sales program, entering into a Sales Agreement with Cantor Fitzgerald & Co. on May 24, 2024. The agreement allows for the sale of up to $19 million of the company's Class A ordinary shares. The sales will be conducted as needed in the market, without any obligation for the company to sell a specific number of shares. The Sales Agent will receive a 3.0% commission on the gross proceeds from the sales. Both Apollomics and the Sales Agent have the right to terminate the agreement under certain conditions, including a significant adverse change in Apollomics' business or financial condition. The offering will conclude once the total sales reach $19 million or if the Sales Agreement is terminated. This move is part of Apollomics' efforts to raise capital through its effective registration statement on Form F-3.

Apollomics Inc., a biopharmaceutical company, has established an 'At the Market' sales program, entering into a Sales Agreement with Cantor Fitzgerald & Co. on May 24, 2024. The agreement allows for the sale of up to $19 million of the company's Class A ordinary shares. The sales will be conducted as needed in the market, without any obligation for the company to sell a specific number of shares. The Sales Agent will receive a 3.0% commission on the gross proceeds from the sales. Both Apollomics and the Sales Agent have the right to terminate the agreement under certain conditions, including a significant adverse change in Apollomics' business or financial condition. The offering will conclude once the total sales reach $19 million or if the Sales Agreement is terminated. This move is part of Apollomics' efforts to raise capital through its effective registration statement on Form F-3.